What is Surgilum?
Surgilum is at the forefront of developing advanced ophthalmic surgical devices, most notably its RoboMarker G2, a smart corneal marking system. This technology is engineered to significantly improve the precision and efficiency of eye surgeries, catering to surgeons who require dependable and accurate marking solutions for procedures such as Toric IOL placement and Femtosecond laser alignment. The company's commitment to user-centric design and cutting-edge technology aims to optimize surgical workflows and ultimately lead to better patient outcomes. Surgilūm's deep industry expertise and recognition through multiple international design awards underscore its position as an innovator in ophthalmic surgical technology.
How much funding has Surgilum raised?
Surgilum has raised a total of $16K across 1 funding round:
Debt
$16K
Debt (2021): $16K with participation from PPP
Key Investors in Surgilum
PPP
Public-Private Partnership
What's next for Surgilum?
With the recent influx of moderate growth capital, Surgilum is strategically positioned for its next phase of expansion. This funding is expected to accelerate the development and market penetration of its innovative ophthalmic surgical devices, particularly the RoboMarker G2. The company's Series A/B growth stage suggests a focus on scaling production, expanding its sales and distribution networks, and potentially investing further in research and development to maintain its competitive edge. Surgilum's trajectory indicates a strong potential for continued innovation and market leadership in the ophthalmic surgical device industry.
See full Surgilum company page
